Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:
Stock analysts at Credit Suisse Group started coverage on shares of Avantor (NYSE:AVTR - Get Rating) in a research report issued to clients and investors on Wednesday, The Fly reports. The brokerage set a "neutral" rating on the stock.
Several other equities research analysts have also issued reports on the stock. William Blair reaffirmed an "outperform" rating on shares of Avantor in a report on Friday, April 29th. Robert W. Baird reduced their target price on shares of Avantor from $44.00 to $34.00 and set an "outperform" rating on the stock in a report on Monday, August 1st. The Goldman Sachs Group reduced their target price on shares of Avantor from $42.00 to $37.00 and set a "buy" rating on the stock in a report on Thursday, July 14th. Morgan Stanley reduced their target price on shares of Avantor from $40.00 to $37.00 and set an "overweight" rating on the stock in a report on Monday, August 1st. Finally, Evercore ISI reduced their target price on shares of Avantor to $35.00 in a report on Tuesday, August 9th. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $39.00.Avantor Stock Performance
Shares of AVTR traded down $0.03 during midday trading on Wednesday, reaching $26.01. The stock had a trading volume of 5,113,228 shares, compared to its average volume of 5,151,274. The firm has a 50 day simple moving average of $29.70 and a 200-day simple moving average of $31.67. Avantor has a one year low of $25.53 and a one year high of $44.37. The firm has a market cap of $17.53 billion, a PE ratio of 27.97, a P/E/G ratio of 2.28 and a beta of 1.30. The company has a current ratio of 1.64, a quick ratio of 1.05 and a debt-to-equity ratio of 1.41.
Avantor (NYSE:AVTR - Get Rating) last announced its earnings results on Thursday, July 28th. The company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.38 by ($0.01). The company had revenue of $1.91 billion for the quarter, compared to the consensus estimate of $1.98 billion. Avantor had a return on equity of 27.14% and a net margin of 8.27%. The business's quarterly revenue was up 2.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.35 EPS. As a group, sell-side analysts anticipate that Avantor will post 1.46 EPS for the current year. Hedge Funds Weigh In On Avantor
Several institutional investors have recently added to or reduced their stakes in the stock. Summit Global Investments bought a new position in Avantor during the second quarter valued at about $1,242,000. Captrust Financial Advisors boosted its position in Avantor by 16.1% during the second quarter. Captrust Financial Advisors now owns 18,446 shares of the company's stock worth $574,000 after purchasing an additional 2,561 shares during the period. Legal & General Group Plc boosted its position in Avantor by 12.9% during the second quarter. Legal & General Group Plc now owns 3,884,233 shares of the company's stock worth $120,799,000 after purchasing an additional 443,410 shares during the period. ExodusPoint Capital Management LP boosted its position in Avantor by 22.7% during the second quarter. ExodusPoint Capital Management LP now owns 54,583 shares of the company's stock worth $1,698,000 after purchasing an additional 10,092 shares during the period. Finally, Walleye Capital LLC boosted its position in Avantor by 169.7% during the second quarter. Walleye Capital LLC now owns 321,963 shares of the company's stock worth $10,013,000 after purchasing an additional 202,575 shares during the period. Institutional investors own 93.24% of the company's stock. About Avantor (Get Rating)
Avantor, Inc provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.See AlsoGet a free copy of the StockNews.com research report on Avantor (AVTR)NYSE Stocks Give Investors a Variety of Quality Options Zoom Video Communications Valuation Is Realigned With Reality The J.M. Smucker Company Proves Why Staples Are Outperforming Will the Real Palantir Please Stand Up? Foot Locker Just Because A Very Tempting Buy
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Avantor, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avantor wasn't on the list.
While Avantor currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:
Tom remains optimistic about investors’ prospects going forward, even as the market reacts to the words of Fed Chair Jerome Powell about “pain ahead.”
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.
MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.
Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.
Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.
MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.
Twitter Facebook StockTwits Financial Juice YouTube
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds
© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.